Breast Cancer Recurrence, Screening Test, CanAssistBreast, India
  • Nacl Accrediated
  • Cap Accrediated
  • Ul Accrediated

OncoStem

CanAssist Breast

Oncostem Whatsapp
Book your test

Articles authored by renowned Indian oncologists

Parikh, P., et. al. Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India. South Asian J Cancer 2021;10:213–219. Doi:https://doi.org/10.1055/s-0041-1742080 ISSN 2278-330X
Oncostem
Krishnamurthy A. Breast cancer prognostic tools: A promising Indian option. Int J Mol Immuno Oncol 2020;5(2):47-8. Doi: 10.25259/IJMIO_15_2020
Canassist breast
Bhattacharyya, GS., et al. Overview of Breast Cancer and Implications of Overtreatment of Early-Stage Breast Cancer: An Indian Perspective. JCO Global Oncology 2020; 6: 789-798. Doi: 10.1200/GO.20.00033
Canassist

Articles authored by OncoStem team

Zhang X., & Gunda A. et. al. Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial
Oncostem
Gunda A. et. al. A comparative analysis of recurrence risk predictions in ER+/HER2-early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast. Breast Cancer Res Treat. 2022 Sep 10. doi: 10.1007/s10549-022-06729-7. Epub ahead of print. PMID: 36085534.
Oncostem
Zhang, X., et. al. 9P-Long term recurrence risk predictions by CanAssist Breast in a sub-cohort of TEAM. ESMO Breast Cancer, Berlin, Germany 3-5 May 2022
Oncostem
Gunda, A., et. al. A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort. The Breast 2022;63:1-8 Doi: https://doi.org/10.1016/j.breast. 2022.02.010
Oncostem
Doval, DC., et. al. Usefulness of CanAssist breast in assessment of recurrence risk in patients of ethnic Indian origin. The Breast 2021; 59:1-7. Doi:10.1016/j.breast.2021.05.007
Oncostem
Somashekhar, SP., et. al. PS4-47. Multi-country clinical validation of CanAssist Breast in Europe indicates robustness of the test. SABC 2020
Oncostem
Sengupta, A., et al. Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX. Cancer Medicine 2020; 0:1-9. Doi: 10.1002/cam4.3495
Oncostem
Patil, P., et al. CanAssist breast: An affordable breast cancer prognostic test validated on Asian patients. ASCO 2020; J Clin Oncol 38: 2020 (suppl; abstr 541). Doi: 10.1200/JCO.2020.38.15_suppl.541
Affordable breast cancer test
Sankaran, S., et al. CanAssist Breast impacting clinical treatment decisions in early-stage HR+ breast cancer patients: Indian scenario. Indian Journal of Surgical Oncology 2019; 1-9. doi: 0.1007/s13193-019-01014-4
Impacting Clinical Treatment
Bakre, M., et al. 242P Clinical validation of CanAssist breast in a Spanish cohort. ESMO 2019. Annals of Oncology, 2019; 30(Supplement_5), mdz240-066. Doi: 10.1093/annonc/mdz240.066
Clinical Validation
Gopalakrishnan, V., et al. Impact of CanAssist-Breast in clinical treatment decisions in early stage HR+ breast cancer patients: ASCO 2019. Asian Scenario. Journal of Global Oncology; 5: no. suppl 109-109. Doi: 10.1200/JGO.2019.5.suppl
immunohistochemistry-based-test
Bakre, M. M., et al. Clinical validation of an immunohistochemistry-based CanAssist Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients.Cancer Medicine 2019; 1-10. Doi: 10.1002/cam4.2049
immunohistochemistry-based-test
Attuluri, AK., et al. Analytical Validation of the immunohistochemistry-based CanAssist Breast Prognostic Test for Prediction of Risk of Recurrence in Hormone Receptor- Positive Breast Cancer, 2019; BMC Cancer 19:249. Doi: 10.1186/s12885-019-5443-5
ER Pr positive test
Ramkumar, C., et al. Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor–Positive Breast Cancer, 2018; Biomarker insights, 13, 1177271918789100. doi: 10.1177/1177271918789100
Her negative test
Prakash, C., et al. Risk stratification in early-stage estrogen receptor+ /HER2-breast cancer patients: Comparative analysis of cost-effective methods, J Curr Onc 2018; 1:1-15
HER2-breast cancer patients
Bakre, M. 4P CanAssist-Breast-an immunohistochemistry based test for risk of recurrence prediction for early stage breast cancer patients: A cost-effective and accurate solution for Asia. ESMO 2018. Annals of Oncology, 29(suppl_9), mdy426-003. Doi: 10.1093/annonc/mdy426.003
immunohistochemistry
Somashekhar, SP., et al. 1675P Risk of recurrence prediction and optimum treatment planning for early-stage breast cancer patients: A cost-effective, accurate and broad based solution for Asia. ESMO 2017. Annals of Oncology, 28(suppl_5). Doi: https://doi.org/10.1093/annonc/ mdx390.047
Recurrence prediction
Ramkumar, C., et al. Assessment of Ki67 As a Prognostic Marker in Hormone Receptor Positive Breast Cancer: A Retrospective Study. J Mol Biomark Diagn 2017; 8:3 Doi: 10.4172/2155-9929.1000336
Hr positive
Govindan, S et. al. Androgen Receptor mRNA levels determine the prognosis in triple-negative breast cancer patients. BMC Cancer, 2020; 20:745
Androgen Receptor mRNA levels

Want to know about your recurrence risk?

to personalize your cancer treatment and reduce the risk & side effects of chemotheraphy